Abstract
Antibody glycosylation has received considerable attention in coronavirus disease 2019 (COVID-19) infections and recently also in vaccination. Antibody glycosylation and in particular immunoglobulin G1 fucosylation levels influence effector functions and are therefore key parameters for assessing the efficacy and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directed immune responses. This review article summarizes and interprets recent research into antibody glycosylation in COVID-19. Experimental approaches for analyzing the glycosylation of SARS-CoV-2-directed antibody responses are evaluated. The pronounced dynamics, effector functions, clinical utility, and regulation of antibody glycosylation in COVID-19 are assessed. Future research on the role of antibody glycosylation in COVID may cover the glycosylation of other antibody classes beyond immunoglobulin G, the regulation of antibody glycosylation, and the role of non-canonical antibody receptors in determining effector functions. Graphical abstract: [Figure not available: see fulltext.]
| Original language | English |
|---|---|
| Pages (from-to) | 335–344 |
| Number of pages | 10 |
| Journal | Glycoconjugate Journal |
| Volume | 39 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2022 |
Bibliographical note
Funding Information:T. P. was supported by the European Union’s Horizon 2020 Research and Innovation programme, under H2020-MSCA-ITN grant agreement number 721815.
Publisher Copyright:
© 2022, The Author(s).
Keywords
- Antibody glycosylation
- COVID-19
- Glycomics, biomarker
- IgG glycosylation
- SARS-CoV-2
